专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015153379A1 FIIXED DOSAGE FORMULATIONS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR AND THE DIURETIC CHLORTHALIDONE 审中-公开
标题翻译：血管紧张素转换酶（ACE）抑制剂和DIALIC CHLORTHALIDONE的混合剂量配方
公开(公告)号：WO2015153379A1
公开(公告)日：2015-10-08
申请号：PCT/US2015/023193
申请日：2015-03-27
申请人： AILEX PHARMACEUTICALS, PVT. LTD. , RAJAN, Dorai , SUD, Himanshu
发明人： RAJAN, Dorai , SUD, Himanshu
IPC分类号： A01N43/52
CPC分类号： A61K31/4035 , A61K9/08 , A61K9/20 , A61K31/401 , A61K38/556 , A61K45/06 , A61K2300/00
摘要： The invention describes fixed dosage formulations of an angiotensin converting enzyme (ACE) inhibitor, preferably Lisinopril and the diuretic, preferably Chlorthalidone in the same pharmaceutically acceptable carrier, for example a tablet, capsule or oral suspension and methods of treating hypertension by administering the fixed dosage formulation of Lisinopril and Chlorthalidone to a patient in need thereof.
摘要翻译：本发明描述了血管紧张素转换酶（ACE）抑制剂，优选赖诺普利和利尿剂，优选氯噻酮在相同药学上可接受的载体例如片剂，胶囊或口服悬浮液中的固定剂量制剂和通过施用固定剂量治疗高血压的方法赖诺普利和氯噻酮的制剂用于有需要的患者。

2. 发明申请

WO2007057872A3 CASEIN-DERIVED ANTIMICROBIAL PEPTIDES AND LACTOBACILLUS STRAINS THAT PRODUCE THEM 审中-公开
标题翻译：产生它们的CASEIN衍生的抗微生物肽和乳酸杆菌菌株
公开(公告)号：WO2007057872A3
公开(公告)日：2007-09-27
申请号：PCT/IE2006000130
申请日：2006-11-20
申请人： TEAGASC NAT DIARY PRODUCTS RES , ROSS PAUL , STANTON CATHERINE , HILL COLIN , FITZGERALD GER
发明人： ROSS PAUL , STANTON CATHERINE , HILL COLIN , FITZGERALD GER
IPC分类号： C07K7/06 , A23J3/34 , A23L1/305 , A61K35/74 , A61K38/08 , A61K38/10 , A61P31/00 , C07K7/08
CPC分类号： C07K14/4732 , A23C9/1322 , A23C9/1585 , A23C19/11 , A23L2/52 , A23L33/135 , A23L33/18 , A23L33/40 , A23V2002/00 , A61K38/556 , C07K14/335 , C12N9/52 , C12R1/23 , A23V2200/324 , A23V2250/546
摘要： The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th November 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
摘要翻译：本发明一般涉及健康促进剂领域，特别是抗微生物剂，并提供提供抗微生物肽的抗微生物肽和细菌菌株。一方面，本发明提供了嗜酸乳杆菌的生物学纯培养物，其菌株DPC6026，其样品已于2005年11月18日以保藏号NCIMB 41354于2005年11月18日在苏格兰阿伯丁国家藏品工业和海洋细菌保藏区存放，或者其能够从乳或乳制品生产的衍生物或突变体，具有抗微生物活性的肽。

3. 发明申请

WO2006114195A1 COMPOSITIONS COMPRISING TRIPEPTIDES INHIBITING ACE 审中-公开
标题翻译：包含抑制ACE的组合物
公开(公告)号：WO2006114195A1
公开(公告)日：2006-11-02
申请号：PCT/EP2006/003266
申请日：2006-03-31
申请人： UNILEVER N.V. , UNILEVER PLC , HINDUSTAN LEVER LIMITED , GERHARDT, Cinderella, Christina , VAN PLATERINK, Christianus, Jacobus , EDENS, Luppo , WOLFRAM, Swen
发明人： GERHARDT, Cinderella, Christina , VAN PLATERINK, Christianus, Jacobus , EDENS, Luppo , WOLFRAM, Swen
IPC分类号： A61K38/01 , A61K38/55 , A23L1/305 , A61P9/12 , A61P3/10
CPC分类号： A61K38/556 , A61K38/018
摘要： The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament.
摘要翻译：本发明描述了MAP和/或ITP或其盐作为营养药物，优选药物的用途。

4. 发明申请

WO2006020884A2 COMBINATION THERAPY FOR DIABETES, OBESITY, AND CARDIOVASCULAR DISEASES USING GDF-8 INHIBITORS 审中-公开
标题翻译：使用GDF-8抑制剂进行糖尿病，肥胖和心脏血管疾病的联合治疗
公开(公告)号：WO2006020884A2
公开(公告)日：2006-02-23
申请号：PCT/US2005/028766
申请日：2005-08-11
申请人： WYETH , TOBIN, James, F.
发明人： TOBIN, James, F.
CPC分类号： A61K38/28 , A61K31/00 , A61K38/05 , A61K38/179 , A61K38/18 , A61K38/556 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/22 , A61K2300/00
摘要： A method of treating obesity, cardiovascular diseases, and disorders of insulin metabolism in a subject, comprising administering to the subject a therapeutically effective amount of a GDF-8 inhibitor, and a therapeutically effective amount of at least one other therapeutic agent which treats the targeted syndrome.
摘要翻译：一种治疗受试者的肥胖症，心血管疾病和胰岛素代谢紊乱的方法，包括向受试者施用治疗有效量的GDF-8抑制剂和治疗有效量的至少一种其它治疗剂，其治疗靶向综合征。

5. 发明申请

WO2004080482A8 USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS TO PREVENT DIABETES IN A SUBJECT WITH CHRONIC HEART FAILURE 审中-公开
标题翻译：使用抗生素转化酶（ACE）抑制剂预防糖尿病患者与慢性心脏衰竭
公开(公告)号：WO2004080482A8
公开(公告)日：2005-09-09
申请号：PCT/CA2004000243
申请日：2004-02-17
申请人： INST CARDIOLOGIE MONTREAL , BOURASSA MARTIAL G , TARDIF JEAN-CLAUDE , DUCHARME ANIQUE
发明人： BOURASSA MARTIAL G , TARDIF JEAN-CLAUDE , DUCHARME ANIQUE
IPC分类号： A61K31/40 , A61K31/41 , A61K38/55 , A61K45/06 , A61P3/10 , A61P9/00
CPC分类号： A61K31/40 , A61K31/41 , A61K38/556 , A61K45/06
摘要： The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P
摘要翻译：本发明涉及血管紧张素转化酶（ACE）抑制剂对预防左心室功能障碍患者糖尿病的作用。进行了一项回顾性研究，以评估ACE抑制剂依那普利对参加“左心室功能障碍研究”（SOLVD）研究的蒙特利尔心脏病研究组患者糖尿病发病率的影响。盲法评估者对空腹血糖（FPG）水平评估临床表现。当2次访视（随访，2.9±1.0年）发现FPG为126 mg / dL（7 mmol / L）时，进行糖尿病诊断。在参加SOLVD研究的291例非糖尿病患者中，其中153例为依那普利，138例为安慰剂。两组基线特征相似。随访期间，40例患者发生糖尿病，依那普利组为9例（5.9％），安慰剂组为31例（22.4％）（P <0.0001）。通过多变量分析，依那普利仍然是发展中糖尿病风险降低最有力的预测指标（风险比为0.22; 95％置信区间，0.10至0.46; P <0.0001）。因此，依那普利可显着降低左心室功能障碍患者的糖尿病发病率，特别是FPG受损患者。

6. 发明申请

WO2005000270A2 INHALABLE FORMULATIONS FOR TREATING PULMONARY HYPERTENSION AND METHODS OF USING SAME 审中-公开
标题翻译：用于治疗肺动脉高压的可吸入制剂及其使用方法
公开(公告)号：WO2005000270A2
公开(公告)日：2005-01-06
申请号：PCT/EP2004/006629
申请日：2004-06-18
申请人： MERCK PATENT GMBH , CHAUDRY, Imtiaz
发明人： CHAUDRY, Imtiaz
IPC分类号： A61K9/12
CPC分类号： A61K9/0078 , A61K31/00 , A61K31/401 , A61K31/404 , A61K31/472 , A61K31/55 , A61K31/5575 , A61K31/5585 , A61K31/675 , A61K38/556 , A61K45/06
摘要： The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
摘要翻译：本发明涉及用于治疗哺乳动物（例如人）中的肺动脉高压的可吸入制剂，其中所述制剂包含至少一种高血压减轻剂，包括但不限于血管紧张素转换酶抑制剂，血管紧张素受体阻断剂， β-阻滞剂，钙通道阻滞剂或血管扩张剂，或其任何组合。本发明的制剂可以是溶液或悬浮液，并且优选适于通过雾化进行给药。本发明还涉及用于治疗患有肺动脉高压的哺乳动物的方法和试剂盒。

7. 发明申请

WO2004071526A1 STORAGE-STABLE AND BIO-STABLE FORMULATIONS OF ACE INHIBITORS, AND METHODS FOR PREPARATION THEREOF 审中-公开
标题翻译： ACE抑制剂的储存稳定和生物稳定配方及其制备方法
公开(公告)号：WO2004071526A1
公开(公告)日：2004-08-26
申请号：PCT/US2003/040132
申请日：2003-12-05
申请人： SIGMAPHARM, INC.
发明人： SPIREAS, Spiridon
IPC分类号： A61K38/55
CPC分类号： A61K9/1694 , A61K9/2054 , A61K9/2059 , A61K31/40 , A61K31/44 , A61K38/556
摘要： The present invention provides storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride, that can be manufactured in a time efficient and cost effective manner. Such formulations can be prepared simply and on a large industrial scale using conventional methods and equipment. The present invention also provides methods for the preparation of highly manufacturable, storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride. Methods for treatment of cardiovascular disorders using storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride, are also provided.
摘要翻译：本发明提供ACE抑制剂的储存稳定和生物稳定的制剂，特别是马来酸依那普利和盐酸喹那普利，其可以以时间有效且具有成本效益的方式制造。可以使用常规方法和设备简单地并且在大型工业规模上制备这些制剂。本发明还提供了制备高度可制造，储存稳定和生物稳定的ACE抑制剂制剂，特别是马来酸依那普利和盐酸喹那普利的制剂的方法。还提供了使用ACE抑制剂的储存稳定和生物稳定制剂，特别是马来酸依那普利和盐酸喹那普利治疗心血管疾病的方法。

8. 发明申请

WO2003099320A1 NEUREGULIN BASED METHODS AND COMPOSITIONS FOR TREATING VIRAL MYOCARDITIS AND DILATED CARDIOMYOPATHY 审中-公开
标题翻译：用于治疗病毒性心肌病和扩张性心脏病的基于神经质的方法和组合物
公开(公告)号：WO2003099320A1
公开(公告)日：2003-12-04
申请号：PCT/CN2002/000349
申请日：2002-05-24
申请人： ZENSUN (SHANGHAI) SCI-TECH.LTD , ZHOU, Mingdong
发明人： ZHOU, Mingdong
IPC分类号： A61K38/18
CPC分类号： A61K38/1883 , A61K31/122 , A61K31/185 , A61K31/355 , A61K31/375 , A61K31/43 , A61K31/7088 , A61K38/00 , A61K38/2013 , A61K38/212 , A61K38/556 , A61K45/06 , A61K48/00 , C07K14/4756 , Y02A50/465 , A61K2300/00
摘要： The present invention relates to compositions and methods for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in a mammal, which method comprises administering to a mammal, to which such prevention, treatment or delay is needed or desirable, an effective amount of a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin, whereby said viral myocarditis or DCM is prevented, treated or delayed. Combinations, kits and pharmaceutical compositions for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in mammals using neuregulins and their enhancers are also provided.
摘要翻译：本发明涉及用于预防，治疗或延迟哺乳动物，特别是人中的病毒性心肌炎或扩张型（充血性）心肌病（DCM）的组合物和方法。更具体地，本发明提供了用于在哺乳动物中预防，治疗或延迟病毒性心肌炎或扩张（充血性）心肌病（DCM）的方法，该方法包括对需要或期望这种预防，治疗或延迟的哺乳动物施用，有效量的神经调节素蛋白或其功能片段，或编码神经调节蛋白或其功能片段的核酸或增强所述神经调节蛋白的产生和/或功能的试剂，由此所述病毒性心肌炎或DCM 被预防，治疗或延迟。还提供了使用神经调节蛋白及其增强剂预防，治疗或延迟哺乳动物中的病毒性心肌炎或扩张型（充血性）心肌病（DCM）的组合物，试剂盒和药物组合物。

9. 发明申请

WO2003090755A1 TREATMENT OF HYPERTENSION IN WOMEN RECEIVING HORMONE REPLACEMENT THERAPY 审中-公开
标题翻译：接受霍尔米尔替代治疗的妇女高血压治疗
公开(公告)号：WO2003090755A1
公开(公告)日：2003-11-06
申请号：PCT/US2003/012596
申请日：2003-03-24
申请人： SCHERING AKTIENGESELLSCHAFT , KARARA, Adel, H.
发明人： KARARA, Adel, H.
IPC分类号： A61K31/585
CPC分类号： A61K31/675 , A61K31/401 , A61K31/565 , A61K31/567 , A61K31/585 , A61K38/553 , A61K38/556 , A61K2300/00
摘要： A method is described to lower blood pressure and effect hormone replacement therapy (HRT) in a hypertensive woman receiving HRT, comprising administering to the woman effective amounts of drospirenone and an estrogen. In one embodiment, the woman is already taking hypertensive medicine when the method is carried out.
摘要翻译：描述了一种在接受HRT的高血压妇女中降低血压并实施激素替代疗法（HRT）的方法，其包括向女性施用有效量的屈螺酮和雌激素。在一个实施方案中，当进行该方法时，该女性已经服用高血压药物。

10. 发明申请

WO2003026622A1 LISINOPRIL COMPOSITIONS HAVING LARGE-PARTICLE DCPD 审中-公开
标题翻译：具有大颗粒DCPD的赖氨酸组合物
公开(公告)号：WO2003026622A1
公开(公告)日：2003-04-03
申请号：PCT/GB2002/004292
申请日：2002-09-20
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , ROBERTS, Ronald, John , BOWEN, David, Brandon
发明人： ROBERTS, Ronald, John , BOWEN, David, Brandon
IPC分类号： A61K9/20
CPC分类号： A61K38/556 , A61K9/2009
摘要： The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g -1 . The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.
摘要翻译：本发明涉及包含赖诺普利和磷酸氢二钙二水合物DCPD的药物组合物，该方法包括将赖诺普利与DCPD混合，比表面积小于1.5m 2 / g。在赖诺普利制剂/组合物中使用大颗粒尺寸的DCPD具有减少形成的赖诺普利降解产物DKP的量的作用，从而增加用较大尺寸的DCPD配制的片剂的保质期，特别是低剂量的DCPD 的赖诺普利。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式